Genentech, a member of the Roche Group, has announced a significant expansion of its initial investment in a new manufacturing facility in Holly Springs, North Carolina. The total commitment has now doubled to approximately $2 billion, marking a pivotal step for the company’s first East Coast manufacturing hub.
Strategic focus and manufacturing scale The expansion builds upon the initial investment announced in May 2025 and the project’s subsequent groundbreaking in August 2025. Key aspects of the facility include:
-
Target therapies: The site is designed to produce next-generation treatments for metabolic conditions, specifically focusing on the growing obesity therapeutic market.
-
Advanced technology: The facility will integrate cutting-edge biomanufacturing processes, automation, and digital platforms to drive operational efficiency.
-
Operational timeline: Production is slated to begin by 2029.
Economic impact and supply chain resilience This increased funding is expected to create 100 additional jobs, bringing the total workforce at the Holly Springs site to over 500 manufacturing roles. This move aligns with Roche and Genentech’s broader $50 billion commitment to U.S. manufacturing, aiming to strengthen domestic production and innovation in collaboration with national goals.
Genentech’s leadership highlighted that the Holly Springs location was chosen for its access to world-class biotech talent and robust infrastructure. The expansion is viewed as a long-term investment to ensure a resilient supply chain and high-quality medicine for patients for years to come.